Scinai Immunotherapeutics Ltd is an innovative biotechnology company focused on developing cutting-edge immunotherapy solutions for cancer and autoimmune disorders. Leveraging its proprietary immune modulation platform, Scinai is advancing a comprehensive clinical pipeline that aims to deliver transformative therapies to enhance patient outcomes. With a seasoned leadership team and a strong commitment to rigorous research, the company is poised to capitalize on the increasing demand for advanced immunotherapeutics in the global healthcare sector. Strategic partnerships further augment Scinai's growth potential, positioning it as a significant contender within the biopharmaceutical industry.
| Revenue (TTM) | $1.21M |
| Gross Profit (TTM) | $-4.00M |
| EBITDA | $-6.92M |
| Operating Margin | -504.00% |
| Return on Equity | -29.20% |
| Return on Assets | -35.80% |
| Revenue/Share (TTM) | $0.43 |
| Book Value | $1.74 |
| Price-to-Book | 0.20 |
| Price-to-Sales (TTM) | 1.03 |
| EV/Revenue | 6.11 |
| EV/EBITDA | 1.13 |
| Quarterly Earnings Growth (YoY) | 87.20% |
| Quarterly Revenue Growth (YoY) | -16.60% |
| Shares Outstanding | $5.17M |
| Float | $2.81M |
| % Insiders | 0.00% |
| % Institutions | 4.74% |
Volatility is currently expanding
Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform. JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update.
JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd.
JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced that members of its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe, taking place next week in Amsterdam, the Netherlands.
Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer programs JERUSALEM, April 24, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SCNI and any ticker you trade — then tracks every position and per-strategy win rate.
